Core Insights - DuPont de Nemours, Inc. reported a fourth-quarter 2025 loss from continuing operations of $108 million or 27 cents per share, an improvement from a loss of $291 million or 70 cents per share in the same quarter last year [1] - Adjusted earnings were 46 cents per share, exceeding the Zacks Consensus Estimate of 43 cents [1] Financial Performance - DuPont's net sales for the quarter reached $1,693 million, remaining flat year over year and surpassing the Zacks Consensus Estimate of $1,684.1 million [2] - Organic sales decreased by 1%, with a 1% positive impact from foreign currency offsetting a 1% decline in volume [2] - The company had cash and cash equivalents of $715 million at the end of the quarter, down approximately 60% year over year, while long-term debt was $3,134 million, down about 41% [5] Segment Performance - The Healthcare & Water Technologies segment reported net sales of $821 million, up 4% year over year, with organic sales growth of 3% and a 1% benefit from currency [3] - The Diversified Industrials segment recorded net sales of $872 million, down 3% year over year, with organic sales dipping 4% but partially offset by a 1% currency benefit [4] Future Outlook - For the first quarter of 2026, DuPont expects net sales of $1,670 million, operating EBITDA of $395 million, and adjusted EPS of 48 cents [6] - For the full year 2026, net sales are projected to be between $7,075 million and $7,135 million, with operating EBITDA estimated at $1,725 million to $1,755 million and adjusted EPS expected to be between $2.25 and $2.30 [6] Stock Performance - DuPont's shares have declined by 42.2% over the past year, compared to a 13.5% decline in the industry [7]